Quick Order

Canine PD-L1 / B7-H1 / CD274 Protein (Fc Tag)

DatasheetReviewsRelated ProductsProtocols
Canine CD274 Protein Product Information
Synonym:PD-L1, B7-H1, CD274
Protein Construction:A DNA sequence encoding the canine CD274 (XP_541302.4) (Met1-Arg236) was expressed with the Fc region of human IgG1 at the C-terminus.
Species:Canine
Expressed Host:Human Cells
Shipping:In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Canine CD274 Protein QC Testing
Purity:> (17.0+77.6) % as determined by SDS-PAGE.
Endotoxin:<1.0 EU per μg protein as determined by the LAL method.
Stability:Samples are stable for up to twelve months from date of receipt at -70℃
Predicted N Terminal:Phe 19
Molecule Mass:The recombinant canine CD274 consists 456 amino acids and predicts a molecular mass of 51.5 kDa.
Formulation:Lyophilized from sterile PBS, pH 7.4.
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us for any concerns or special requirements.
Canine CD274 Protein Usage Guide
Storage:Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution:A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Canine CD274 Protein SDS-PAGE
Canine PD-L1 / B7-H1 / CD274 Protein (Fc Tag) SDS-PAGE

CD274 Related Pathways

Other CD274 Recombinant Protein Products
Expression host: Human Cells  
    10084-H05H-20
    10084-H05H-100
    20 µg 
    100 µg 
    Add to Cart
    Description: Active  
    Expression host: Human Cells  
    • Slide 1
    10084-H02H-100
    10084-H02H-200
    100 µg 
    200 µg 
    Add to Cart
    Description: Active  
    Expression host: Human Cells  
    • Slide 1
    10084-H08H-200
    10084-H08H-100
    200 µg 
    100 µg 
    Add to Cart
    Description: Active  
    Expression host: Human Cells  
    • Slide 1
    50010-M03H-100
    50010-M03H-200
    100 µg 
    200 µg 
    Add to Cart
    Description: Active  
    Expression host: Human Cells  
    • Slide 1
    50010-M08H-100
    50010-M08H-200
    100 µg 
    200 µg 
    Add to Cart
    Expression host: Human Cells  
    • Slide 1
    50010-M02H-200
    50010-M02H-100
    200 µg 
    100 µg 
    Add to Cart
    Expression host: Human Cells  
    • Slide 1
    • Slide 1
    80450-R02H-100
    80450-R02H-200
    100 µg 
    200 µg 
    Add to Cart
    Expression host: Human Cells  
    • Slide 1
    80450-R08H-200
    80450-R08H-100
    200 µg 
    100 µg 
    Add to Cart
    Expression host: Human Cells  
    • Slide 1
    90251-C08H-100
    90251-C08H-200
    100 µg 
    200 µg 
    Add to Cart
    Expression host: Human Cells  
    • Slide 1
    90251-C02H-100
    90251-C02H-200
    100 µg 
    200 µg 
    Add to Cart
    PD-L1/B7-H1/CD274 Background

    Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

    Canine PD-L1/B7-H1/CD274 References
  • Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
  • Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
  • Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.
  • Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
  • Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.
  • Product nameProduct name
    Size / Price
    Catalog: 70110-D02H-200
    List Price: 
    Price:      (You Save: )
    Contact Us
    Images
    • Canine PD-L1 / B7-H1 / CD274 Protein (Fc Tag) SDS-PAGE
      All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
      Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"